MedTrace Logo

Epileptiform Activity During REM Sleep in Alzheimer's Disease

NCT03923569 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2021-07-28

No results posted yet for this study

Summary

Recent clinical data showed that patients with Alzheimer Disease (AD) might present epilepsy at early stages of the disease (Cretin et al., 2016, Vossel et al., 2016). In mice models of Alzheimer disease, preclinical researchers observed an increase of epileptic events during Rapid Eye Movement (REM) sleep, which is very unusual. This study aims at testing if patients with AD present an exacerbation of epileptic events during REM sleep, which could constitute an early biomarker of the disease. Investigators will evaluate the incidence of epilepsy during each sleep stage in 40 patients with early or moderate forms of AD and in 40 healthy subjects. Investigators will also look for a link between epilepsy during sleep in AD participants and memory performances, brain damage (by using MRI scans) and in the case of patients, the phenotype of the Apolipoprotein E(ApoE) gene.

Conditions

  • Alzheimer Disease, Early Onset

Interventions

DIAGNOSTIC_TEST

Overnight polysomnography

Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test

DIAGNOSTIC_TEST

blood sample

blood sample for genetic testing of the Apolipoprotein E

DIAGNOSTIC_TEST

high-resolution MRI scan

Evaluation of anomalies in brain structure and functional resting state connectivity

BEHAVIORAL

neuropsychological evaluation

neuropsychological evaluation including episodic memory tests before an overnight polysomnography

Sponsors & Collaborators

  • Centre de Recherches sur la Cognition Animale (CRCA - UMR5169 CNRS/UPS)

    collaborator UNKNOWN

  • Centre de Recherche Cerveau & Cognition (CerCo - UMR5549 CNRS/UPS)

    collaborator UNKNOWN

  • Toulouse NeuroImaging Center (ToNIC - UMR 1214 Inserm/UPS)

    collaborator UNKNOWN

  • Fondation Plan Alzheimer

    collaborator OTHER

  • IHNPS/FHU HoPeS

    collaborator UNKNOWN

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Lionel Dahan, PHD · Centre de Recherches sur la Cognition Animale (CRCA), UMR CNRS 5169

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-29
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03923569 on ClinicalTrials.gov